http://purl.org/np/RAFhIgZdjjKeLs0DMocZruzFNTvkRyUqfZTzIn5p9QePg#Head http://purl.org/np/RAFhIgZdjjKeLs0DMocZruzFNTvkRyUqfZTzIn5p9QePg http://www.nanopub.org/nschema#hasAssertion http://purl.org/np/RAFhIgZdjjKeLs0DMocZruzFNTvkRyUqfZTzIn5p9QePg#assertion http://purl.org/np/RAFhIgZdjjKeLs0DMocZruzFNTvkRyUqfZTzIn5p9QePg http://www.nanopub.org/nschema#hasProvenance http://purl.org/np/RAFhIgZdjjKeLs0DMocZruzFNTvkRyUqfZTzIn5p9QePg#provenance http://purl.org/np/RAFhIgZdjjKeLs0DMocZruzFNTvkRyUqfZTzIn5p9QePg http://www.nanopub.org/nschema#hasPublicationInfo http://purl.org/np/RAFhIgZdjjKeLs0DMocZruzFNTvkRyUqfZTzIn5p9QePg#pubinfo http://purl.org/np/RAFhIgZdjjKeLs0DMocZruzFNTvkRyUqfZTzIn5p9QePg http://www.w3.org/1999/02/22-rdf-syntax-ns#type http://www.nanopub.org/nschema#Nanopublication http://purl.org/np/RAFhIgZdjjKeLs0DMocZruzFNTvkRyUqfZTzIn5p9QePg#assertion http://purl.obolibrary.org/obo/DOID_7148 https://w3id.org/biolink/vocab/category https://w3id.org/biolink/vocab/Disease http://purl.org/np/RAFhIgZdjjKeLs0DMocZruzFNTvkRyUqfZTzIn5p9QePg#association http://www.w3.org/1999/02/22-rdf-syntax-ns#object http://purl.obolibrary.org/obo/DOID_7148 http://purl.org/np/RAFhIgZdjjKeLs0DMocZruzFNTvkRyUqfZTzIn5p9QePg#association http://www.w3.org/1999/02/22-rdf-syntax-ns#predicate https://w3id.org/biolink/vocab/treats http://purl.org/np/RAFhIgZdjjKeLs0DMocZruzFNTvkRyUqfZTzIn5p9QePg#association http://www.w3.org/1999/02/22-rdf-syntax-ns#subject https://identifiers.org/drugbank:DB00026 http://purl.org/np/RAFhIgZdjjKeLs0DMocZruzFNTvkRyUqfZTzIn5p9QePg#association http://www.w3.org/1999/02/22-rdf-syntax-ns#type http://www.w3.org/1999/02/22-rdf-syntax-ns#Statement http://purl.org/np/RAFhIgZdjjKeLs0DMocZruzFNTvkRyUqfZTzIn5p9QePg#association http://www.w3.org/2000/01/rdf-schema#label kineret is an interleukin 1 receptor antagonist indicated for rheumatoid arthritis ra reduction in signs and symptoms and slowing the progression of structural damage in moderately to severely active rheumatoid arthritis in patients 18 years of age or older who have failed 1 or more disease modifying antirheumatic drugs dmards 1 1 cryopyrin associated periodic syndromes caps treatment of neonatal onset multisystem inflammatory disease nomid 1 2 kineret is indicated for the reduction in signs and symptoms and slowing the progression of structural damage in moderately to severely active rheumatoid arthritis ra in patients 18 years of age or older who have failed 1 or more disease modifying antirheumatic drugs dmards kineret can be used alone or in combination with dmards other than tumor necrosis factor tnf blocking agents see warnings and precautions 5 2 kineret is indicated for the treatment of neonatal onset multisystem inflammatory disease nomid http://purl.org/np/RAFhIgZdjjKeLs0DMocZruzFNTvkRyUqfZTzIn5p9QePg#association https://w3id.org/biolink/vocab/association_type https://w3id.org/biolink/vocab/ChemicalToDiseaseOrPhenotypicFeatureAssociation http://purl.org/np/RAFhIgZdjjKeLs0DMocZruzFNTvkRyUqfZTzIn5p9QePg#association https://w3id.org/biolink/vocab/provided_by https://w3id.org/um/NeuroDKG http://purl.org/np/RAFhIgZdjjKeLs0DMocZruzFNTvkRyUqfZTzIn5p9QePg#association https://w3id.org/biolink/vocab/relation https://w3id.org/um/neurodkg/SymptomaticReliefIndication https://identifiers.org/drugbank:DB00026 https://w3id.org/biolink/vocab/category https://w3id.org/biolink/vocab/Drug http://purl.org/np/RAFhIgZdjjKeLs0DMocZruzFNTvkRyUqfZTzIn5p9QePg#provenance http://purl.org/np/RAFhIgZdjjKeLs0DMocZruzFNTvkRyUqfZTzIn5p9QePg#assertion http://www.w3.org/ns/prov#wasAttributedTo https://orcid.org/0000-0002-1468-3557 http://purl.org/np/RAFhIgZdjjKeLs0DMocZruzFNTvkRyUqfZTzIn5p9QePg#pubinfo http://purl.org/np/RAFhIgZdjjKeLs0DMocZruzFNTvkRyUqfZTzIn5p9QePg#sig http://purl.org/nanopub/x/hasAlgorithm RSA http://purl.org/np/RAFhIgZdjjKeLs0DMocZruzFNTvkRyUqfZTzIn5p9QePg#sig http://purl.org/nanopub/x/hasPublicKey MIGfMA0GCSqGSIb3DQEBAQUAA4GNADCBiQKBgQCODwZkXojpEKwk7Ldj2oPPfCstvqrcpgCaTLo235K7ht9C7E1GCkLvUuL2b4VWXJTcZx/hxgDauR8hUeYq/lS6tfTL9yFZsnfl+PWYDyz7vv6N+wJVx2LL8bO6ntCjcOzvW2t2WUeF12Sb6b3I6uOYP0N8iQKts1WasY/yEYKAHQIDAQAB http://purl.org/np/RAFhIgZdjjKeLs0DMocZruzFNTvkRyUqfZTzIn5p9QePg#sig http://purl.org/nanopub/x/hasSignature TKmHDr+S1heELpvWg70G6WPxWUmYZAW5//r2s/5T/SLe4Pmzo0uhwXUnggDRnGfevQb1Ooms0+6TzRJfJHyBcgEw3l1PDXO7t9Z5pNcup7ir5Wd3sCesTpdg6KwUd4/0VDF6P5i9PTm89bFAGKAwYgGZkn98jFL/OcOshIhOajs= http://purl.org/np/RAFhIgZdjjKeLs0DMocZruzFNTvkRyUqfZTzIn5p9QePg#sig http://purl.org/nanopub/x/hasSignatureTarget http://purl.org/np/RAFhIgZdjjKeLs0DMocZruzFNTvkRyUqfZTzIn5p9QePg http://purl.org/np/RAFhIgZdjjKeLs0DMocZruzFNTvkRyUqfZTzIn5p9QePg http://purl.org/dc/terms/created 2021-06-12T12:56:30.695+02:00 http://purl.org/np/RAFhIgZdjjKeLs0DMocZruzFNTvkRyUqfZTzIn5p9QePg http://purl.org/dc/terms/creator https://orcid.org/0000-0002-1468-3557 http://purl.org/np/RAFhIgZdjjKeLs0DMocZruzFNTvkRyUqfZTzIn5p9QePg https://w3id.org/np/o/ntemplate/wasCreatedFromProvenanceTemplate http://purl.org/np/RANwQa4ICWS5SOjw7gp99nBpXBasapwtZF1fIM3H2gYTM http://purl.org/np/RAFhIgZdjjKeLs0DMocZruzFNTvkRyUqfZTzIn5p9QePg https://w3id.org/np/o/ntemplate/wasCreatedFromPubinfoTemplate http://purl.org/np/RAA2MfqdBCzmz9yVWjKLXNbyfBNcwsMmOqcNUxkk1maIM http://purl.org/np/RAFhIgZdjjKeLs0DMocZruzFNTvkRyUqfZTzIn5p9QePg https://w3id.org/np/o/ntemplate/wasCreatedFromTemplate http://purl.org/np/RAManV5GZI01JKzW_IPcfOXoiFTcZMmsV7qTCLkdzr4Gs